Keyword: Teva Pharmaceutical Industries
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.
Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.
Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.
Active Biotech and Teva delivered more bad news from their clinical development of laquinimod, this time from a phase 2 trial in Huntington’s disease.
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
Teva is ending a phase 3 trial of its CGRP blocker in chronic cluster headache after an analysis showed it was unlikely to meet its primary endpoint.
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.
The oral CGRP drug ubrogepant met its endpoints in a second phase 3 migraine trial, setting it up for an NDA in 2019.
Eli Lilly presented a post hoc analysis of its monthly migraine therapy galcanezumab, one of a new class of targeted preventive drugs.
The decision, which Alder described as mutual, leaves the biotech without a permanent leader in the runup to filing for approval of its migraine drug.